California is currently home to 5603 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
Recruiting
The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Loma Linda University Health, Loma Linda, California
Conditions: Postpartum Complication, Maternal Hypertension, High Blood Pressure
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: City of Hope, Duarte, California
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: OPN - Oncology Physician Network, Arcadia, California
Conditions: Extensive Stage Small Cell Lung Cancer
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Recruiting
With this research study has following goals * To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated. * To learn more about side effects of palbociclib in combination with chemotherapy; * To learn more about the biological effects of palbociclib on the cells in your body
Gender:
ALL
Ages:
25 years and below
Trial Updated:
01/22/2025
Locations: Lucile Packard Children's Hospital Stanford, Stanford, California
Conditions: Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome
Recruiting
This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X Syndrome (FXS). Eligible participants will participate in up to an 18-week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to \< 30 years will be eligible to participate.
Gender:
ALL
Ages:
Between 3 years and 29 years
Trial Updated:
01/22/2025
Locations: Science 37, Culver City, California
Conditions: Fragile X Syndrome
A Study of Prucalopride in Breastfeeding Women With Constipation
Recruiting
Prucalopride is a medicine used to treat constipation. The main aim of the study is to measure prucalopride concentrations in breast milk. Other aims are to check the growth and development of babies breastfed by their mothers who took prucalopride and to check if the babies had any side effects. During the study, participants will provide one set of milk samples over 24 hours using an electric breast pump. Breast milk samples will be collected at home and will be shipped to the laboratory. Al... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of California San Diego, La Jolla, California
Conditions: Chronic Idiopathic Constipation (CIC)
Reducing Suicide Risk in Older Veterans Using Problem Solving Therapy
Recruiting
Suicide is a national crisis, especially among older Veterans for whom evidence-based suicide prevention efforts are lacking. This proposal responds to the national priority to develop and improve interventions for suicide prevention, with a focus on at-risk older Veterans. The randomized control trial will compare VA usual care, which is suicide safety planning, with brief Problem Solving Therapy and suicide safety planning. This study uses Problem Solving Therapy because it has support from ou... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
01/22/2025
Locations: VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California
Conditions: Suicidal Ideation, Depressive Disorder, Anxiety Disorders, Post Traumatic Stress Disorder
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
Recruiting
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
01/22/2025
Locations: Upsher-Smith Clinical Trial Site #15, La Jolla, California
Conditions: Migraine Disorders
Pulsed Electromagnetic Field (PEMF) Therapy for Post-operative Pain Following Orthopedic Surgery
Recruiting
The primary objective of this study is to prospectively determine, at 10 days after orthopedic shoulder or knee surgery, if pulsed electromagnetic field (PEMF) therapy is beneficial in reducing patient-reported post-operative pain, as measured by visual analog scale (VAS). The amount of pain medication taken daily and the physical function outcome scores after surgery and PEMF treatment will also be measured.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Stanford University, Redwood City, California
Conditions: Knee Injuries, Shoulder Injuries, Pain, Postoperative
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
Recruiting
This is a phase IV, prospective, open label, randomized-controlled study that will compare radial access with state-of-the-art femoral access in patients without ST-segment elevation acute myocardial infarction undergoing cardiac catheterization. Subjects will be randomized 1:1 into 2 treatment groups: radial access and state-of-the-art femoral access. Randomization will be performed in blocks of 50 per site. Similarly, a second sub-randomization will be performed in the femoral access group int... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: San Francisco VA Medical Center, San Francisco, California
Conditions: Patient Satisfaction, Vascular Access Complication
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: UC San Diego, La Jolla, California
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Recruiting
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: City of Hope, Duarte, California
Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma